Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Genet Metab Rep ; 2: 47-50, 2015 Mar.
Article in English | MEDLINE | ID: mdl-28649527

ABSTRACT

Lysinuric protein intolerance (LPI) is a rare autosomal recessive disorder caused by mutations in the SLC7A7 located on the chromosome 14q11.2. LPI is most prevalent in Finland (1:50,000), Northern Japan (1:60,000) and Italy. Cases have also been reported in Spain and the United States. Here we report two siblings of Mexican descent. The older child was diagnosed at the age of three with severe chronic respiratory insufficiency leading to her demise. In contrast, the younger child was diagnosed soon after birth and dietary therapy has led to a stable life. Genetic analysis revealed a previously unreported deletion in the SLC7A7 gene. Additional research is needed to clarify the role of lysine in the pathophysiology of pulmonary proteinosis and herpes infections.

2.
PLoS One ; 9(2): e90258, 2014.
Article in English | MEDLINE | ID: mdl-24587303

ABSTRACT

OBJECTIVE: Remote Ischemic Postconditioning (RIPC) is a promising therapeutic intervention wherein a sub-lethal ischemic insult induced in one organ (limb) improves ischemia in an organ distant to it (brain). The main objective of this study was to investigate the long-term functional effects of delayed RIPC in a neonatal hypoxia-ischemia (HI) rat model. METHOD: 10 day old rat pups were subjected to delayed RIPC treatment and randomized into four groups: 1) Sham, 2) HI induced, 3) HI +24 hr delayed RIPC, and 4) HI +24 hr delayed RIPC with three consecutive daily treatments. Neurobehavioral tests, brain weights, gross and microscopic brain tissue morphologies, and systemic organ weights were evaluated at five weeks post surgery. RESULTS: HI induced rats performed significantly worse than sham but both groups of delayed RIPC treatment showed improvement of sensory motor functions. Furthermore, compared to the HI induced group, the delayed RIPC treatment groups showed no further detrimental changes on brain tissue, both grossly and morphologically, and no changes on the systemic organ weights. CONCLUSION: Delayed RIPC significantly improves long term sensory motor deficits in a neonatal HI rat model. A 24 hr delayed treatment does not significantly attenuate morphological brain injury but does attenuate sensory motor deficits. Sensory motor deficits improve with both a single treatment and with three consecutive daily treatments, and the consecutive treatments are possibly being more beneficial.


Subject(s)
Brain/blood supply , Hindlimb/blood supply , Hypoxia-Ischemia, Brain/therapy , Ischemic Postconditioning , Motor Activity , Recovery of Function , Animals , Animals, Newborn , Brain/physiopathology , Disease Models, Animal , Hypoxia-Ischemia, Brain/physiopathology , Maze Learning , Organ Size , Rats , Rats, Sprague-Dawley
3.
Stroke ; 45(3): 828-34, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24425124

ABSTRACT

BACKGROUND AND PURPOSE: Transforming growth factor-ß (TGF-ß) overproduction and activation of the TGF-ß pathway are associated with the development of brain injury following germinal matrix hemorrhage (GMH) in premature infants. We examined the effects of GMH on the level of TGF-ß1 in a novel rat collagenase-induced GMH model and determined the effect of inhibition of the TGF receptor I. METHODS: In total, 92 seven-day old (P7) rats were used. Time-dependent effects of GMH on the level of TGF-ß1 and TGF receptor I were evaluated by Western blot. A TGF receptor I inhibitor (SD208) was administered daily for 3 days, starting either 1 hour or 3 days after GMH induction. The effects of GMH and SD208 on the TGF-ß pathway were evaluated by Western blot at day 3. The effects of GMH and SD208 on cognitive and motor function were also assessed. The effects of TGF receptor I inhibition by SD208 on GMH-induced brain injury and underlying molecular pathways were investigated by Western blot, immunofluorescence, and morphology studies 24 days after GMH. RESULTS: GMH induced significant delay in development, caused impairment in both cognitive and motor functions, and resulted in brain atrophy in rat subjects. GMH also caused deposition of both vitronectin (an extracellular matrix protein) and glial fibrillary acidic protein in perilesion areas, associated with development of hydrocephalus. SD208 ameliorated GMH-induced developmental delay, improved cognitive and motor functions, and attenuated body weight loss. SD208 also decreased vitronectin and glial fibrillary acidic protein deposition and decreased GMH-induced brain injury. CONCLUSIONS: Increased level of TGF-ß1 and activation of the TGF-ß pathway associate with the development of brain injury after GMH. SD208 inhibits GMH-induced activation of the TGF-ß pathway and leads to an improved developmental profile, partial recovery of cognitive and motor functions, and attenuation of GMH-induced brain atrophy and hydrocephalus.


Subject(s)
Brain Injuries/drug therapy , Brain Injuries/physiopathology , Intracranial Hemorrhages/drug therapy , Intracranial Hemorrhages/physiopathology , Nervous System Diseases/drug therapy , Nervous System Diseases/physiopathology , Transforming Growth Factor beta/antagonists & inhibitors , Adult , Animals , Atrophy , Blotting, Western , Cerebral Ventricles/pathology , Extracellular Matrix Proteins/metabolism , Female , Glial Fibrillary Acidic Protein/metabolism , Humans , Hydrocephalus/etiology , Hydrocephalus/pathology , Immunohistochemistry , Nervous System Diseases/etiology , Neurologic Examination , Pregnancy , Pteridines/pharmacology , Pteridines/therapeutic use , Rats , Rats, Sprague-Dawley , Signal Transduction/physiology , Survival , Vitronectin/metabolism , Weight Loss/drug effects
4.
Analyst ; 129(9): 855-9, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15343403

ABSTRACT

Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. SMA is caused by the homozygous loss of the survival motor neuron 1 (SMN1) gene. A nearly identical copy gene exists known as SMN2, however, due to an aberrant splicing event, the SMN2 gene fails to produce sufficient full-length protein to protect against disease development in the absence of SMN1. While a number of compounds have recently been identified that can stimulate full-length survival motor neuron (SMN) expression from the nearly identical copy SMN2, one of the difficulties has been the lack of a highly reproducible and quantitative means to measure the levels of SMN protein. To develop a technique that allows the rapid and highly sensitive measurement of SMN protein, a Surface Plasmon Resonance (SPR) application has been developed. The ability to quantify unassociated SMN protein and monitor the binding of SMN with other proteins in solution using a SPR sensor in less than 15 min and at low ng mL(-1) levels in HEPES Buffer Saline (HBS) has been achieved. The detection limit for the specific binding of SMN in HBS pH 7.4 solution is 0.99 ng mL(-1) with non-specific binding accounting for approximately 30% of the signal. Quantification of SMN is based on an immunoassay performed on the gold surface of the SPR sensor. 16-mercaptohexadecanoic acid (MHA) was reacted with dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS) to form a pre-activated thiol (MHA-NHS). Antibodies for SMN were then coupled to the sensor with the pre-activated thiol. Sensor specificity was examined with mixtures of myoglobin (MG) and SMN. SMN sensor response decreases by more than 60% when MG was added to SMN. The decrease in sensor response can be attributed to non-specific binding of SMN to MG, verified with a sensor for MG.


Subject(s)
Motor Neurons/chemistry , Nerve Tissue Proteins/analysis , Biosensing Techniques , Fiber Optic Technology , Humans , Optical Fibers , Recombinant Proteins/analysis , Surface Plasmon Resonance
SELECTION OF CITATIONS
SEARCH DETAIL
...